Document Detail


Are activated clotting times helpful in the management of anticoagulation with subcutaneous low-molecular-weight heparin?
MedLine Citation:
PMID:  11579347     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Enoxaparin has recently been shown to be superior to unfractionated heparin in patients with unstable angina/non-ST-elevation myocardial infarction. Theoretical advantages of low-molecular-weight heparin versus unfractionated heparin include a higher ratio of anti-Xa to anti-IIa activity (3:1 for enoxaparin), a more predictable dose response that precludes the need for frequent monitoring, and the convenience of subcutaneous administration. Both activated partial thromboplastin time and activated clotting time (ACT) are used to monitor anticoagulation with heparin, and ACTs are now standard during percutaneous coronary intervention (PCI) with heparin. At doses of up to 90 mg, subcutaneous enoxaparin leads to a modest dose-related increase in activated partial thromboplastin time, but the effect on ACT is unknown. METHODS: Thrombolysis In Myocardial Infarction (TIMI) 11A was a multicenter, dose-ranging trial to evaluate the safety and tolerability of subcutaneous enoxaparin in patients with unstable angina/non-ST-elevation myocardial infarction. We obtained peak (mean 4.3 hours after enoxaparin) and trough (mean 11.5 hours after enoxaparin) anti-Xa levels and ACTs for 26 patients in the TIMI 11A trial. RESULTS: Despite doses of enoxaparin in the range of 89 +/- 19 mg every 12 hours and significant increases in anti-Xa levels even at trough, there was no change in the ACT measured by HemoTec and only a small increase with Hemachron. The correlation of peak Hemachron ACT with peak anti-Xa levels was poor (R = 0.5, P =.08). CONCLUSIONS: In contrast to heparin, ACTs are not useful for assessment of anticoagulation with subcutaneous enoxaparin and should not be relied on in patients receiving enoxaparin who require acute PCI. Studies to determine the optimal dose, safety, and efficacy of enoxaparin in patients undergoing PCI are underway.
Authors:
T D Henry; D Satran; L L Knox; C L Iacarella; D D Laxson; E M Antman
Related Documents :
16234627 - Appropriate invasive and conservative strategies for patients with non-st elevation acu...
11812067 - Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-ye...
15078587 - Should people on aspirin avoid ibuprofen? a review of the literature.
17556877 - The role of clopidogrel in the management of ischemic heart disease.
12415227 - Prognostic implication of ergonovine echocardiography in patients with near normal coro...
20736447 - Coronary artery bypass grafting after recent or remote percutaneous coronary interventi...
Publication Detail:
Type:  Journal Article; Multicenter Study    
Journal Detail:
Title:  American heart journal     Volume:  142     ISSN:  1097-6744     ISO Abbreviation:  Am. Heart J.     Publication Date:  2001 Oct 
Date Detail:
Created Date:  2001-10-01     Completed Date:  2001-12-07     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  0370465     Medline TA:  Am Heart J     Country:  United States    
Other Details:
Languages:  eng     Pagination:  590-3     Citation Subset:  AIM; IM    
Affiliation:
Hennepin County Medical Center, Minneapolis, MN, USA. henry003@tc.umn.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angina Pectoris / blood,  drug therapy*
Anticoagulants / pharmacology,  therapeutic use*
Blood Coagulation / drug effects*
Dose-Response Relationship, Drug
Drug Administration Schedule
Enoxaparin / administration & dosage,  pharmacology,  therapeutic use*
Heart Catheterization
Humans
Injections, Subcutaneous
Insect Proteins*
Myocardial Infarction / blood,  drug therapy*
Salivary Proteins and Peptides / blood
Whole Blood Coagulation Time
Chemical
Reg. No./Substance:
0/Anticoagulants; 0/Enoxaparin; 0/Insect Proteins; 0/Salivary Proteins and Peptides; 0/anticoagulant factor Xa protein, Aedes aegypti

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Relationship of the Glu298Asp polymorphism of the endothelial nitric oxide synthase gene and early-o...
Next Document:  Decade-long trends (1986 to 1997) in the medical treatment of patients with acute myocardial infarct...